Other parameters were also evaluated, such as age, tumor size, P53, Ki-67 index, lymph node metastasis, presence of TILs, and expression of immune checkpoint markers, including PD-1 and PD-L1 (Table 3). The gene discussed is PDCD1; the disease is metastatic malignant neoplasm in the lymph nodes.